Categories: News

Coventry and Alan Buerger Move to Dismiss Abacus Lawsuit

Motion underscores that Abacus’s claims lack merit as Lapetus, its key life expectancy provider, shut its doors August 31

- Advertisement -

FORT WASHINGTON, Pa., Sept. 3, 2025 /PRNewswire/ — Coventry First LLC (“Coventry”) and its Co-Founder and Executive Chairman, Alan H. Buerger, today announced that they have filed a Motion to Dismiss the complaint brought by Abacus Global Management, Inc. (“Abacus”) (NASDAQ: ABL) in the U.S. District Court for the Middle District of Florida on August 29, 2025. The full Motion to Dismiss can be found here.

- Advertisement -

In the filing, Coventry and Mr. Buerger express their view that Abacus’s lawsuit is an effort to silence constitutionally protected debate. As the Motion states:

- Advertisement -

“The First Amendment expresses ‘a profound national commitment to the principle that debate on public issues should be uninhibited, robust, and wide-open.’ Abacus, however, seeks to flip that principle on its head. Faced with criticism about serious problems of its own making, Abacus brought this meritless lawsuit to muzzle those who have highlighted the truth or expressed their constitutionally protected opinions. That it cannot do.”

- Advertisement -

The Motion also highlights that Abacus invested in and relied heavily upon Lapetus Solutions, Inc. (“Lapetus”) as its primary life expectancy provider — but Lapetus publicly announced that it shut down all operations effective August 31, 2025. This development underscores the concerns raised regarding Abacus’s practices and the importance of open debate about the life settlement industry. 

- Advertisement -

“Abacus’s complaint is an attempt to silence robust debate on important issues affecting the life settlement industry, including the reliability of life expectancy estimates,” said Mr. Buerger. “Transparent disclosures advance the interests of investors, regulators, and the life settlement market as a whole, and the First Amendment protects the right to voice opinions and concerns, particularly on matters of such public interest.”

- Advertisement -

About Coventry

- Advertisement -

Coventry is the leader and creator of the secondary market for life insurance. For more than 20 years, we have been driving the industry forward and expanding opportunities for life insurance policyowners. Coventry’s deep experience combined with a fierce commitment to consumer rights makes Coventry the clear market leader, a position we use to raise industry standards and expand consumer choice. To date, we have delivered more than $6 billion to policyowners who no longer have a need for their policies. To learn more about Coventry, please visit Coventry.com. 

- Advertisement -

Media Contacts:

- Advertisement -

Prosek Partners for Coventry
Andy Merrill / Kiki Tarkhan
Pro-Coventry@prosek.com 

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/coventry-and-alan-buerger-move-to-dismiss-abacus-lawsuit-302544516.html

- Advertisement -

Recent Posts

Crypto News: AlphaPepe Presale Records Surge in Whale Accumulation As Bitcoin Price Prediction Eyes $180,000

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…

2 hours ago

Crypto Market News: AlphaPepe Finalizes Tier-1 Exchange Shortlist as XRP Price Prediction Targets $5.00

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…

2 hours ago

Qoder Version 1.0 Released: Full Automation of Code Generation, Verification & Delivery

SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…

2 hours ago

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…

2 hours ago

ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026

– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract…

2 hours ago

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast…

2 hours ago